Dariohealth Corp Stock Price, News & Analysis

DarioHealth Corp. (Nasdaq: DRIO) reported a Q2 2022 revenue of $6.2 million, marking a 17.5% increase from Q2 2021. The six-month revenue reached $14.2 million, a 60.8% increase. Key developments include a new contract with a national health plan, projected to add nearly 10 million members. The company reported a net loss of $18 million for Q2 2022, with an operating loss of $17.4 million. Operating expenses decreased by 5.2% year-over-year. Dario continues to transition to its B2B2C focus while maintaining a strong pipeline for future growth.

DarioHealth Corp. (Nasdaq: DRIO) announced new research demonstrating that its digital health solutions effectively improve glycemic control in rural residents with Type 2 diabetes, similar to outcomes seen in urban populations. The study, presented at the ADCES Annual Conference, revealed significant reductions in average blood glucose levels over 12 months for both groups. This suggests that Dario's platform can address healthcare challenges faced by rural communities, potentially enhancing access to effective chronic condition management.

DarioHealth Corp. (NASDAQ: DRIO) will announce its financial results for Q2 2022 on August 15, 2022, at 8:30 am ET. The announcement will be followed by a conference call hosted by CEO Erez Raphael, President Rick Anderson, and CFO Zvi Ben-David. Participants should dial in 10 minutes early to the numbers provided. A replay will be available shortly after the event until September 15, 2022. DarioHealth provides digital health solutions for chronic conditions, aiming to enhance patient management through personalized interventions and data analytics.

DarioHealth Corp. (Nasdaq: DRIO) presented new research at the American Psychological Association Annual Convention on August 4-6, 2022, highlighting its digital behavioral health solution's effectiveness. Findings revealed that 72% of users with clinically elevated depression symptoms saw a reduction over 12 weeks, while 44% experienced significant improvements. Additionally, 68% of users with moderate to severe anxiety reported improvements, with 40% achieving clinically significant reductions. The studies emphasize Dario's integrated approach, associating better health outcomes for individuals with chronic conditions.

Solera Health announces a partnership with DarioHealth to enhance hypertension management solutions. This collaboration introduces a streamlined system for payers and employers to access Dario's digital therapeutics, promoting a comprehensive approach to chronic conditions.

Dario's solution includes a connected blood pressure monitor and a smart app, supporting user engagement through personalized coaching. The CDC reports nearly half of U.S. adults have high blood pressure, contributing to $198 billion in healthcare costs annually. This partnership aims to improve patient outcomes and reduce related costs.

DarioHealth Corp. (NASDAQ: DRIO) has secured a $50 million senior secured term loan facility from OrbiMed, enhancing its financial stability. The initial $25 million is available immediately, with another $25 million contingent on achieving revenue thresholds by June 30, 2023. This funding aims to support DarioHealth's digital therapeutics platform, especially in chronic disease management. The company now potentially has over $100 million in capital access, allowing it to invest in its growing B2B market segment without needing further capital raises.

DarioHealth Corp. (Nasdaq: DRIO) highlighted breakthroughs in chronic condition management at the American Diabetes Association's 82nd Scientific Sessions on June 3-7, 2022. Three studies revealed significant enhancements in glucose control and reductions in blood pressure for users facing diabetes and hypertension. Key findings include:

• Two-thirds of users improved systolic blood pressure by 13 mmHg.
• High-risk Type 2 diabetes users reduced blood glucose by 15%.
• Average blood glucose decreased by 14%-15% across diverse ethnicities.

The integrated solutions demonstrate Dario's potential to transform chronic condition management.